Skip to main content
. 2024 Aug 4;15:6613. doi: 10.1038/s41467-024-50881-1

Fig. 4. ARF6 status in tumours distinguishes ICB outcomes.

Fig. 4

a Systemic anti-PD-1 treated for 5 weeks duration. Includes mice that developed tumours within 35–77 (Arf6WT) days or 49–91 (Arf6f/f) days after Cre injection. Kaplan–Meier log-rank test. D/C = discontinued treatment. b Association of ICB treatment outcome with mRNA levels of ARF6 in transcriptomes of pretreatment melanoma biopsies (Cancer-Immu expression analysis, aggregated data from n = 13 queried melanoma clinical studies, adjusted p-values, Benjamini and Hochberg procedure, LR = likelihood ratio with df = 1, PFS n = 140, OS n = 160 in each high and low cohort). See also Supplementary Fig. 4. Source data are provided as a Source Data file.